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ABSTRACT
In 2012, approximately 153,000 new cancer cases and almost 95,000 cancer-related deaths were recorded in 
Poland. Despite an increase in new cancer cases, the number of deaths decreased as compared to the previous 
year. It is estimated that in Poland in 2012 more than 364,000 people were alive with cancer having been diagnosed 
during the previous 5 years. Lung cancer remains the leading cause of mortality and the greatest social challenge 
among all malignancies. In the female population, both morbidity and mortality from lung cancer are increasing, 
while both of these indicators are steadily decreasing among men. Non-small cell lung cancer (NSCLC) is the 
most commonly diagnosed group of lung cancers, accounting for more than 80% of histological diagnoses. 
Lung cancer is characterized by unfavorable five-year survival rates (in Poland approximately 14%) and relatively little 
therapeutic progress for decades. A growing number of genetic determinants of the development and progression 
of lung cancer have been identified recently with impact on new treatments, in particular molecularly targeted 
agents. In recent years, results of randomized phase II and phase III clinical trials and retrospective analyses have 
indicated significant improvements in outcomes of overall survival, progression free survival, the objective response 
rate, as well as the quality of life in groups of patients with certain genetic abnormalities in tumor cells. The wide 
availability of epidermal growth factor receptor (EGFR) inhibitors in the first or second line treatment of patients 
with advanced lung cancer allows for prolonged progression-free survival of patients with mutations in the EGFR 
gene by 66% compared to those receiving standard chemotherapy. However, precise selection of patients for 
ALK inhibitors in second-line treatment of advanced NSCLC patients with ALK gene rearrangement allows for the 
prolongation of median overall survival to approximately thirty months, a target which has never been obtained in 
this group of patients. The drug programs currently funded by the National Health Fund do not cover ALK inhibi-
tors, which have to meet challenging pharmacoeconomic requirements. The growing role of economic analyses 
in the process of updating and implementating oncological drug programs in Poland has a crucial impact on the 
availability of new treatment options for patients. It seems, therefore that verification of the updated results and 
the correct interpretation of pharmacoeconomic data is of greatest importance. 
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Introduction
Quality of life and survival are currently the main 
parameters considered during the interpretation of re-
sults of clinical trials with new antineoplastic treatment 
methods. Direct comparison of clinical trial results with 
the current standard of care is very difficult, due to the 
complexity of evaluation and multiplicity of analytical 
methods, as well as changing requirements for design-
ing clinical trials. As there is lack of head-to-head 
comparisons of particular therapeutic methods, making 
adequate decisions according to the availability of the 
new modalities is especially challenging. Growing con-
tradictions between the general progress of medicine 
and the financial possibilities of publicly-funded bodies 
has led to the tightening of criteria of health technology 
assessment and establishing price levels on which certain 
technology may be reimbursed. Many clinical trials are 
conducted in very small subpopulations of patients with 
particular molecular abnormalities in cancer cells and 
despite the multinationality of the studies, it is difficult 
to obtain results with sufficient statistical power. On 
the other hand, the expectations of patients regarding 
their access to new treatment methods is still increasing, 
a factor which is especially important in patients with 
lung cancer and hematological malignancies.
Lung cancer is the most common cancer worldwide, 
with approximately 1.6 million patients suffering from 
this disease annually. Additionally, lung cancer is the 
leading cause of cancer-related deaths both in the 
female and male genders (in general there are approx. 
1.4 million deaths each year). Non-small cell lung cancer 
(NSCLC) is the most commonly diagnosed subtype of 
lung cancer, accounting for more than 80% of histo-
logically diagnosed diseases. At diagnosis, nearly half of 
patients are in advanced/metastatic stage. The median 
of survival time in this group of patients currently ranges 
between 8 and 12 months. In a proportion of patients, 
there is the possibility of using targeted treatments, 
which significantly improve progression-free survival, 
overall survival, as well as quality of life [1].
Recent research efforts led to the identification of 
driving molecular abnormalities that serve as predic-
tive features for the benefit from novel cancer targeted 
therapies. It has been shown that treatment with tyrosine 
kinase inhibitors (TKIs) of epidermal growth factor re-
ceptor (EGFR) and TKIs for ALK is beneficial in some 
patients, which justifies a personalized approach in the 
process of choosing an optimal management strategy. 
The clinical trials in patients with cancers driving by 
molecular abnormalities (KRAS, HER2, BRAF genes 
mutations and ROS1, RET and NTRK gene rearrange-
ment) are currently during phases I, II and III. The 
discovery of the predictive value of EGFR mutation 
and ALK gene rearrangement in NSCLC patients has 
facilitated further treatment optimization by distinguish-
ing subpopulations obtaining real clinical benefits from 
certain treatments. Moreover, the results of clinical trials 
and retrospective analyses have indicated the high ef-
fectiveness of ALK inhibitors in patients with advanced 
NSCLC and ALK gene rearrangement, leading to 
prolongation of median of overall survival to a period 
ranging between 2–3 years.
Epidemiology
In the second half of the 20th century, lung cancer 
morbidity among men in Poland dramatically increased. 
In contrast, in the last two decades this trend has con-
strained and reversed due to a reduction in smoking. 
Morbidity and mortality due to lung cancer in young 
men, as well as those middle-aged, has decreased by 
up to 30%. At the same time, in the last decade, lung 
cancer mortality and morbidity rates among women have 
dramatically increased. Indeed, this was the main reason 
that, since 2007, lung cancer has become the leading 
cause of cancer-related mortality in women, preced-
ing even breast cancer (Tables 1, 2). A region-based 
analysis performed by Polish National Cancer Registry 
(Krajowy Rejestr Nowotworów) indicates that lung cancer 
mortality rates among women are higher in big urban 
areas than in surrounding regions [2]. In all provinces 
in Poland, lung cancer is the most prevalent cancer in 
men, with subsequent malignant neoplasms including 
prostate, colon, bladder and stomach cancers. Depend-
ing on particular provinces, lung cancer is the second or 
third most prevalent cancer among women. Moreover, 
lung cancer has become the most common cause of 
cancer-related deaths among women in up to 11 out of 
16 provinces in Poland.
The rearrangement of the ALK gene [ALK (+)] is 
observed in 3–5% NSCLC patients, mainly those pre-
senting adenocarcinoma histology and more commonly 
in non-smokers [3, 4]. In Poland, this produces the ab-
solute number of approximately 240–360 patients with 
stage IV disease, of whom approximately 60–100 would 
be qualified for treatment with ALK inhibitors after 
the failure of previous lines of treatment. Detection of 
such number of translocations of the ALK gene would 
need 1200–2000 molecular assessments of primary tu-
mor samples from patients after the failure of first line 
chemotherapy. 
The main risk factor in all lung cancer patients is ac-
tive smoking while the risk of lung cancer development 
is proportional to the duration of smoking, the number 
of cigarettes consumed and age of starting to smoke. 
Other risk factors have definitely a lower significance in 
the whole population and they are as follows: radiation 
exposure, asbestos exposure, cancerogenous chemical 
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Table 1. Lung cancer morbidity in Poland in 2012
Sex Absolute 
number
Percent Crude rate 
per 100,000
Standardized rate 
per 100,000
Male 15,177 19.9 81.4 51.2
Female 6,660 8.7 33.5 17.8 
Source: National Cancer Registry (Krajowy Rejestr Nowotworów)
Table 2. Deaths in patients with lung cancer (C34) in Poland in 2012
Sex Absolute 
number
Percent Crude rate 
per 100,000
Standardized rate 
per 100,000
Male 16,182 30.7 86.7 53.5
Female 6,434 15.3 32.4 16.4
Source: National Cancer Registry (Krajowy Rejestr Nowotworów)
substances and some heavy metals (cadmium, lead, 
nickel, arsenic), as well as the long-lasting exposure to 
the toxic fumes of coal and liquid fuels [5]. 
Genetic and molecular diagnostics
The diagnostics of lung cancer, together with dis-
ease staging and treatment, is currently a very complex 
process which needs a multi-specialized approach with 
a team involving a clinical oncologist, a radiotherapist, 
a cardiothoracic surgeon, a radiologist, a pathologist, 
a specialist in molecular biology and a palliative care. 
Reimbursement of targeted treatments for patients 
with advanced NSCLC has additionally influenced the 
need to organize multi-specialized teams and to develop 
guidelines regarding histology sample processing. The 
availability of oncology molecular tests, including the 
assessment of biomarkers of treatment response (mo-
lecular predictive factors), plays an essential role in the 
accurate qualifying of lung cancer patients to targeted 
treatment. The recognition of such factors is of great-
est importance in the making of therapeutic decisions, 
including matching targeted drugs to the cancer’s 
genetic profile (genotyping). Constraints regarding ac-
cess to molecular testing could impair the effectiveness 
of treatment, as well as generate additional costs for 
the healthcare system. ALK gene rearrangement is the 
second molecular test which, together with the EGFR 
mutation test, is performed on NSCLC patients aiming 
at qualification to molecular-targeted treatments. Ac-
cording to European and Polish recommendations about 
molecular testing in NSCLC patients, an assessment of 
ALK gene rearrangement is the standard of care in the 
process of qualifying patients for treatment with ALK 
inhibitors. ALK gene rearrangement assessment should 
be performed in all patients with adenocarcinoma and 
in those with lung cancer presenting an adenocarcinoma 
component. It is recommended to assess the status of 
EGFR gene mutation at first, while ALK gene rearrange-
ment should be performed in patients without somatic 
mutations in the EGFR gene. The turn-around time re-
garding the results of EGFR gene mutation and/or ALK 
gene rearrangement tests should not exceed 10 working 
days from the delivery the histological material to the 
genetic laboratory. It is recommended to do preliminary 
assessment of ALK gene rearrangement based on an im-
munohistochemical assay and, in case of positive results, 
this should be confirmed by FISH. The time of waiting 
for genetic assessment results should be a maximum of 
5 working days [6]. 
Recently published evidence suggests an increasing 
significance of the analysis of plasma free-circulating 
DNA and cancer cells in peripheral blood. This could 
be especially useful in prophylactic testing, noninvasive 
diagnostics, prognosis of the course of the disease and 
the monitoring of molecular therapy effectiveness.
At the beginning of 2015, an additional procedure 
of oncology diagnostic reimbursement (e.g. an oncol-
ogy package), was implemented in Poland making 
a healthcare providers able to finance preliminary di-
agnostics tests and in-depth diagnostics based on lump 
sums dedicated to particular cancers, providing that 
the timing outlined for diagnostic procedures is kept. 
Lump sums for deep diagnostics of lung cancer patient 
also include an amount for pathological tests. Accord-
ing to the new regulations, molecular and genetic tests 
should be performed in outpatient care, within so-called 
in-depth diagnostics. Moreover, the healthcare provider 
is expected to abide by the rules of medical management 
presented in the standards of care, published as rules 
and regulations, as well as the guidelines and recom-
mendations issued by scientific societies of specialists 
from particular disciplines [7]. Since treatment with 
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Table 3. Comparison of standardized rates of 5-years relative 
survival rates in patients with lung cancer diagnosed 
between 2000 and 2007. Data are presented as percentage 
(%) of relative survival (95% confidence interval)
Country Lung cancer
Germany* 15.6 (15.3–16.0)
Island 13.9 (11.5–16.7)
Belgium* 15.4 (14.9–16.0)
Switzerland* 15.3 (14.4–16.3)
Austria 16.7 (16.1–17.2)
Finland 11.5 (10.8–12.2)
Sweden 14.7 (14.1–15.3)
Italy* 14.3 (14.0–14.6)
France* 13.8 (13.2–14.4)
Norway 12.9 (12.3–13.6)
Portugal* 11.2 (10.6–11.9)
Netherlands 13.4 (13.1–13.7)
Malta 10.3 (7.9–13.0)
Spain* 10.7 (10.2–11.2)
Europe (mean) 13.0 (12.9–13.1)
Slovenia 10.7 (9.9–11.6)
Denmark 10.3 (9.8–10.8)
Czech Republic 11.5 (11.0–11.9)
Great Britain and Ireland 9.0 (8.8–9.1)
Estonia 11.7 (10.5–13.0)
Slovakia 10.3 (9.6–11.0)
Croatia 14.8 (14.2–15.5)
Lithuania 9.1 (8.4–9.9)
Poland* 14.4 (13.8–15.0)
Bulgaria 6.2 (5.8–6.7)
Latvia 12.2 (11.2–13.2)
*Countries in which cancers were not registered in whole population. Source: 
De Angelis R et al. (EUROCARE-5 Working Group). Cancer survival in Europe 
1999–2007 by country and age: results of EUROCARE-5 — a population-based 
study. Lancet Oncology 2014; 15: 23–34.
ALK inhibitors is not available within National Health 
Fund (NHF) reimbursement, ALK gene rearrangement 
testing is commonly done on a commercial basis (cost of 
FISH assay — approx. 700–900 PLN) [8, 9].
Possibilities of targeted treatment 
in patients with ALK (+) NSCLC
The possibility of using subsequent therapeutic 
strategies is based on toxicity and the effectiveness of 
the first line treatment. Evidence published during last 
decade has revealed a number of molecular aberra-
tions in NSCLC patients which has contributed to the 
development of new tyrosine kinase inhibitors, blocking 
ALK, MET, ROS1 and HER2 related pathways, cur-
rently playing an increasing role in the targeted treat-
ment of lung cancer. After the accelerated registration 
of crizotinib in the United States, the American Food 
and Drug Administration (FDA) designated this drug 
as a breakthrough treatment, enabling the a reduction 
in the time of the registration process for two additional 
drugs from this group: ceritinib (LDK378) and alectinib 
(RO5424802).
Crizotinib is the first orally available, small-molecule 
TKI registered by the European Medicine Agency 
(EMA), inhibiting ALK, MET and ROS1 kinases. Re-
sults of in vitro and in vivo studies have shown that 
crizotinib inhibits the phosphorylation of ALK and signal 
transduction, which leads to the shutting down of the 
cell cycle and apoptosis induction [10]. In a multicenter, 
open-label, single arm phase II clinical trial (PROFILE 
1005), aimed at assessing the effectiveness of crizotinib 
treatment in patients with advanced ALK (+) NSCLC 
after failure of at least 2 chemotherapy lines, the median 
progression-free survival (PFS) was 8.1 months and the 
objective response rate (ORR) was 60% (the median 
of response duration was 10.5 months). This trial also 
confirmed the favorable safety profile of crizotinib [11]. 
It was very important for clinical practice to assess qual-
ity of life and cancer-related symptoms, using EORTC 
(European Organization for Research and Treatment 
of Cancer Quality of Life Questionnaire) QLQ-C30 and 
QLQ-LC13 questionnaires. After 2 treatment cycles, 
a significant improvement in dyspnea, cough control, 
pain and asthenia was observed.
In 2013 the results of the phase III randomized clini-
cal trial PROFILE 1007 were published, which evaluated 
the efficacy of crizotinib in second line treatment in com-
parison with pemetrexed or docetaxel [12]. PROFILE 
1007 was the first phase III clinical trial comparing di-
rectly efficacy of crizotinib with standard chemotherapy 
in patients presenting advanced NSCLC with ALK gene 
rearrangement. Among 347 eligible patients, 173 were 
treated with crizotinib resulting in a progression-free 
survival which was significantly prolonged (primary 
endpoint) with a median PFS of 7.7 months in patients 
treated with crizotinib and 3 months in the group with 
standard chemotherapy (HR = 0.49; 95% confidence 
interval [CI] 0.37–0.64; p < 0.001). A subsequent sub-
groups analysis showed clinical benefits regarding the 
improvement of PFS in patients with brain metastases 
(HR = 0.67; 95% CI 0.44–1.03), in whom prognosis was 
especially poor.
ORR was 65% (95% CI 58–72%) in crizotinib-treat-
ed patients and 20% (95% CI 14–26%) in chemotherapy 
group, respectively (p < 0.001). A preliminary analysis 
showed no significant difference in overall survival, 
probably due to the use of crizotinib in the second line 
after disease progression in 62% of patients previously 
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treated with chemotherapy (crossover design). In both 
groups, the overall survival time exceeded 20 months, 
which is spectacular therapeutic success in a group 
of patients receiving second line palliative treatment. 
Furthermore, this trial indicated that crizotinib was well 
tolerated. Indeed, the majority of adverse events noted 
in crizotinib-treated patients were of grade 1 or 2, except 
elevated aminotransferase levels, which were observed 
at grade 3 and 4 in 16% of patients. In general, adverse 
events of grade 3 and 4 were noted in 19% of patients 
in the group treated with standard chemotherapy and 
13% of crizotinib treated patients. Of note, the necessity 
of using an anti-nausea drug in the group with standard 
chemotherapy was significantly higher than in the crizo-
tinib group (67% vs. 20%). In the PROFILE 1007 study 
the patients treated with crizotinib reported an improve-
ment in the general quality of life as compared with the 
patients receiving standard chemotherapy (p < 0.001), 
who had no improvement in the quality of life.
In 2014 Ou et al. published a retrospective analysis 
of data from PROFILE 1001 and PROFILE 1005 stud-
ies, regarding clinical benefits in previously treated ALK 
(+) patients, with continuous treatment with crizotinib, 
even beyond disease progression [13]. The median 
survival from initial crizotinib treatment in patients 
treated beyond progression was 29.6 months as com-
pared with 10.8 months in patients who discontinued 
therapy upon progression of the disease (HR = 0.30, 
95% CI, 0.19–0.46, p < 0.0001). A multivariate analysis 
revealed that treatment beyond progression was signifi-
cantly associated with improved overall survival. The 
median survival after disease progression in patients 
who continued treatment with crizotinib beyond dis-
ease progression was more than 4-fold longer than in 
patients who discontinued crizotinib after disease pro-
gression (16.4 months vs. 3.9 months, HR = 0.27, 95% 
CI 0.17–0.42, p < 0.0001). Such long survival time was 
previously unreachable in this group of patients. These 
results may be explained mainly by progressions in the 
central nervous system (crizotinib is characterized by low 
brain-blood barrier penetration) and further treatment 
effectiveness, observed in progressive disease limited to 
intracranial localization after brain radiotherapy.
The results of presented analysis suggest that the 
progression of disease limited only to intracranial 
lesions needs a specific approach during crizotinib 
treatment. Continuation of crizotinib treatment after 
radiotherapy of brain metastases provides further 
clinical benefits regarding systemic disease control. 
Lower drug concentrations in the central nervous 
system (CNS) are the main reason for the failure of 
treatment of lesions in this localization. A subgroup of 
138 patients with disease progression presenting new 
metastatic lesions was analyzed. It was indicated that 
in up to 51% of patients treated with crizotinib beyond 
progression, this progression was limited only to the 
central nervous system.
The efficacy analysis of crizotinib treatment in par-
ticular subgroups indicates special clinical benefits which 
may be observed in NSCLC patients with brain metasta-
ses. In January 2015 the results of a retrospective analysis 
of the effectiveness of treatment in 275 patients with 
brain metastases participating in PROFILE 1005 and 
1007 studies were published [14]. The rates of general, 
as well as intracranial disease control were higher in pa-
tients with asymptomatic brain metastases. The median 
time to progression was 7 months (95% CI 6.7–16.4) in 
the group of patients who had previously not undergone 
radiation treatment due to metastases in the CNS and 
13.2 months (95% CI 9.9 – not reached) in the group 
of patients who had undegone previous radiotherapy. 
At the time of data analysis, the final results of overall 
survival were not available due to the high number of 
on-treatment patients. Nevertheless, a preliminary es-
timated probability of 12-months survival was 59% in 
the subgroup of patients untreated due to metastases to 
the CNS, 64% in previously irradiated patients due to 
metastases in the CNS and 69% in subgroup of patients 
with no metastases at recruitment. 
The efficacy and safety of crizotinib used in the 
first line treatment in patients with advanced ALK (+) 
NSCLC was evaluated in a randomized, open-label 
phase III study, PROFILE 1014. Patients (n = 343) were 
randomly assigned in a ratio 1:1 to the crizotinib-treated 
group or to the group receiving pemetrexed and plati-
num derivatives (cisplatin or carboplatin). According 
to the protocol, it was allowed in both arms to continue 
or to start treatment with crizotinib after disease pro-
gression (crossover design). The primary endpoint was 
PFS. Secondary endpoints included: ORR, OS, safety 
and quality of life. 
The study results, presented during Annual Meeting of 
the American Society of Clinical Oncology (ASCO) and 
published in The New England Journal of Medicine, sup-
ported the benefits of crizotinib over chemotherapy with 
pemetrexed and platinum analogue in the improvement 
of PFS (10.9 months vs. 7.0 months, HR = 0.454, 95% 
CI 0.346–0.596, p < 0.0001). The objective response rate 
was statistically significantly higher in crizotinib treated 
patients (74% vs. 45%, p < 0.0001). Although at the pre-
sentations of results there was no statistically significant 
improvement in overall survival (HR = 0.821, 95% CI, 
0.536–1.255, p = 0.1804), finally, 109 patients in the che-
motherapy group received crizotinib upon treatment fail-
ure, a factor which could have significantly influenced lack 
of difference between groups regarding overall survival. 
Adverse event incidences in both groups were consistent 
with previous trial results in patients with advanced ALK 
(+) NSCLC. The most common reported adverse events 
(regardless of reason) in the crizotinib-treated group 
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were visual disturbances and gastrointestinal disease. To 
conclude, the PROFILE 1014 study indicated significant 
improvement in first line treatment results regarding PFS 
and ORR in patients with advanced ALK (+) NSCLC as 
compared with standard chemotherapy and an acceptable 
safety profile of treatment with crizotinib (Table 4) [15]. 
However, the above-presented results should be treated 
as preliminary due to the continuing nature of the study, 
planned to end in July 2016 [16].
In 2014, a report was published indicating the clinical 
benefits of crizotinib treatment also in NSCLC patients 
with ROS1 gene rearrangement [17]. These results need 
to be confirmed in larger, prospective clinical trials, 
which are very difficult to obtain taking into consid-
eration the relatively rare ROS1 gene rearrangement 
among patients with NSCLC (approx. 2%). These 
results additionally support the increasing need for 
genetic profiling of tumor samples already at the stage 
of qualifying for treatment, which, in the near future, 
will be an efficient way to improve treatment results 
and optimize treatment costs in lung cancer patients.
Polish experience
Since ALK inhibitors are not systematically avail-
able in Poland, only a limited group of patients was 
treated with crizotinib (ceritinib and alectinib were not 
used outside clinical trials — personal communication). 
All data regarding the results from all patients treated 
in Poland with crizotinib were collected, enabling an 
analysis of the clinical benefits regarding PFS and OS 
in this group of patients (Figs. 1, 2).
The median PFS among patients treated with 
crizotinib was 15.4 months. It is to be noted that after 
46 months (maximal observation time) the median of 
overall survival was not reached. Despite the retrospec-
tive nature of the analysis and the small sample size, 
which limits conclusions, survival times confirms data 
on crizotinib activity.
Cost-effectiveness of new technologies 
used in treatment of NSCLC patients
The growing costs of treatment are especially chal-
lenging in oncology. As a result, the implementation of 
innovative therapeutic methods in this area of health-
care is connected with especially restrictive measures, 
taking into consideration clinical, economic and social 
aspects. Antineoplastic drugs are a growing part of 
budgets allotted to the public healthcare system [18]. 
An increasing number of new discoveries in oncology 
and accelerated marketing authorization of a growing 
Table 4. Summary of clinical trial results according to the survival rates and objective response rates in NSCLC 
patients treated with crizotinib
Study Patients group Median of 
progression-free 
survival (months)
Objective 
response rate 
(ORR)
Median of overall 
survival 
(months)
PROFILE 1005 Patients treated with crizotinib 
in 2 and further lines
8.1  
(95% CI 6.8–9.7)
60% ND
PROFILE 1007 
(comparison 
with standard 
chemotherapy)
Patients treated 
with crizotinib in 2 line
7.7  
(HR = 0.49; 95% CI 
0.37–0.64, p < 0.001)
65% 20.3 
(indirect analysis)
Patients with brain metastases 
treated with crizotinib 
in 2 line
HR = 0.67; 95% CI 
0.44–1.03
ND ND
Retrospective 
analysis of data from 
PROFILE 1001 and 
PROFILE 1005 studies 
(Ou 2014)
Patients after diseae 
progression treated 
with crizotinib in 2 
and further lines
(majority with 
brain metastases)
ND ND 29.6  
(HR = 0.30, 
95% CI 0.19–0.46, 
p < 0.0001)
PROFILE 1014 
(comparison with 
standard 
chemotherapy)
Patients treated 
with crizotinib in 1 line
10.9 
(HR = 0.454. 95% CI 
0.346–0.596, 
p < 0.0001)
74% ND
NA — lack of data
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Figure 2. Overall survival in NSCLC patients treated in Poland 
(2 and 3 treatment lines). Source: data from Dept. of Oncology 
and Radiotherapy, Medical University of Gdansk
Figure 1. Progression-free survival in NSCLC patients treated 
in Poland (2 and 3 treatment lines). Source: data from Dept. 
of Oncology and Radiotherapy, Medical University of Gdansk
number of promising drugs have increased pressure to 
improve the cost-effectiveness of new drug-based tech-
nologies and decrease the costs of diagnostic molecular 
and genetic tests. Although this direction is justified, it 
could lead to wide differences in the cost-effectiveness of 
the same medical technology not only between different 
countries, but also within the same country. Addition-
ally, the improved treatment results in NSCLC patients 
treated by crizotinib shown in very recent publications 
comparing it with standard chemotherapy, have led to 
situations where the results of cost-effectiveness analy-
sis with using of incremental cost-effectiveness ratio 
(ICER), performed in many previous economic analyses 
are no longer valid. 
The long-term benefits, as well as therapeutic-added 
value, have been extrapolated in economic evaluations 
using mathematical models, supplemented by data 
from available short-term analyses of clinical effective-
ness. Since the results of such modeling more com-
monly determine the availability of new technologies 
in the treatment of potentially fatal diseases, validation 
of modeling methods and verification of results play 
a crucial role, with incremental – cost-effectiveness 
ratio (ICER) being one of the most commonly cited 
[19]. The ICER ratio is a subtraction of costs between 
comparing treatment options divided by the subtraction 
of effects expressed most often as a quality-adjusted life 
year (QALY). The policy makers correlate ICER values 
with an assumptive threshold of cost-effectiveness in 
a particular country (region). New treatment options, for 
which an ICER value exceeds this threshold are treated 
as cost-ineffective and are commonly not reimbursed 
(Poland) or are financed within special, separate budgets 
(Great Britain).
Another difficulty in the objective evaluation of 
cost-effectiveness could be the fact that prolonged 
survival time, indicated in randomized phase III clini-
cal trials is very often influenced by crossing over, e.g. 
by patients from control group taking the experimental 
drug due to ethical reasons. Therefore, it should be 
underlined that although the cost-effectiveness of new 
technology is a variable relating to survival rates esti-
mated in the mathematical model, it also includes the 
incremental cost of new technology, the timing land-
scape of analysis, the legal regulations in force in given 
country and social values, attributed to the analyzed 
health states [20]. As already mentioned, the results 
of the new retrospective clinical trials with criziotinib, 
indicating possible gains in survivial time that led to 
median overall survival of nearly 30 months, could sig-
nificantly change the cost of an additional life year in 
this group of patients. Moreover, the comparator is an 
additional factor that significantly influences the ICER 
value. In the comparison of crizotinib with standard 
chemotherapy in second line treatment in NSCLC pa-
tients, pemetrexed and docetaxel could be considered 
comparators. Nevertheless, the results of retrospective 
analyses suggest that ALK gene rearrangement presence 
is connected with a higher susceptibility to pemetrexed, 
which enforces the use of this drug as a comparator in 
economic models [21, 22]. It is also worth mentioning 
that in the majority of clinical trials with EGFR TKIs 
inhibitors used in NSCLC patients, no survival benefit 
was noted.
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Table 5. Expenditures of health services connected to the 
treatment of cancer per capita in particular European Union 
(EU) countries in 2009 [30]
Country Cost per capita (€)
All cancers Lung cancer
Bulgaria 16 1
Lithuania 18 1
Romania 20 1
Latvia 26 2
Malta 39 2
Cyprus 45 2
Portugal 53 3
Hungary 39 4
Estonia 45 4
Poland 37 5
Czech Republic 57 5
Slovakia 57 5
Spain 90 5
Slovenia 72 6
Great Britain 85 7
France 110 7
Belgium 94 8
In general for EU 102 8
Sweden 105 8
Italy 114 9
Denmark 104 10
Greece 111 10
Finland 151 12
Netherlands 130 13
Ireland 139 13
Austria 144 13
Germany 182 16
Luxemburg 184 21
An additional difficulty in economic analysis, espe-
cially regarding antineoplastic drugs, is the frequent lack 
of final results of overall survival, even a long time after 
marketed authorization. If one estimates the overall sur-
vival benefit based on a surrogate like PFS, it should be 
highlighted that many trials have supported the utility of 
PFS in NSCLC. As a standard, the additional life years 
of patient are multiplied during the economic analysis 
by the value of a statistical life year (VSLY) to convert it 
into national currency units. VSLY values differ between 
countries. In a review of articles published in 2015 in 
The Journal of the American Medical Association it was 
noted that the mean cost of an additional QALY gained 
by using a new medical technology most often ranged 
between $40,000 and $400,000. Currently, $200,000 is 
recognized as optimal [23]. As taxpayer-funded bodies 
very often demand final results regarding the effect of 
a new technology on overall survival time, in the pre-
sented review it was assessed as the mean time period 
since the publication of PFS data till the publication 
of OS data. In case of NSCLC, this time was between 
7 and 46 months. 
Currently, to optimize the expenditure incurred on 
new medical technologies many countries use new fi-
nancial mechanisms improving the access of the patients 
to high-cost, innovative methods of treatment. The new 
reimbursement regulations, introduced in Poland in 
2012 enabled the improvement of the cost-effectiveness 
of many medicinal products through the use of risk-shar-
ing schemes (RSS) [24]. Similar solutions were already 
introduced in practice in last decade in the healthcare 
systems in many countries. In addition, crizotinib has 
been approved by publicly funded bodies in the major-
ity of countries using RSS [25–28]. At the same time, 
Polish reimbursement regulations mentioned above 
implemented very restrictive requirements regarding 
pharmacoeconomic indices, identical for all new drugs 
and regardless of diagnosis. This led to demands for 
drug manufacturers to show cost-effectiveness also for 
new, high-cost antineoplastic drugs. It seems that in 
Polish conditions, the financing of costs of ALK gene 
rearrangement testing by drug manufacturers could 
be an additional factor, significantly optimizing the 
cost-effectiveness of treatment with ALK inhibitors. 
It should be also underlined that according to 
the NHF data, in 2011 there were 58,657 procedures 
(diagnostic and therapeutic) reimbursed in patients with 
confirmed diagnosis of lung cancer (ICD10–C34). At the 
same time, aggregated investment of the NHF for lung 
cancer on the national level amounted to 751.8 million 
PLN [29]. As NHF analyses have indicated, currently, 
lung cancer ranks as the third most common oncological 
disease (after breast and colorectal cancer) in spending 
for public healthcare system. Furthermore, comparing 
the costs of services connected with lung cancer per 
capita in particular countries in European Union (EU) 
it was shown that Poland is among those countries with 
the lowest expenditure in this area (Table 5) [30].
Summary
The morbidity of lung cancer in Poland is continu-
ously growing. The crucial factors for decreasing of mor-
bidity and mortality in the nearest future in this group of 
patients will be as follows: development of primary and 
secondary prophylaxis methods, diagnosis at the very 
early stage of disease and the access of patients to the 
new, effective treatment methods. The latter are charac-
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terized by very dynamic progress. One of the indicators 
of this progress could be increasing number of innovative 
medicinal products registered by FDA and EMA in this 
setting. ALK inhibitors are one of the most important 
group of targeted treatment for which genetic predic-
tive factors have been identified, enabling an adequate 
selection of patients with the highest benefits from this 
treatment. The very first two ALK inhibitors (crizotinib, 
ceritinib) were registered in an accelerated procedure 
due to their high effectiveness shown in clinical trials 
[31]. The FDA is still proceeding with another ALK 
inhibitor (alectinib), which has already been authorized 
in Japan [32]. Currently published evidence indicates 
the possibility of the prolongation of median survival 
time in patients with advanced NSCLC with ALK gene 
rearrangement of up to 30 months. It should be noted 
that significant clinical benefits could also be obtained 
by patients with brain metastases, who previously had 
previously very poor prognosis. The mean overall sur-
vival in this group of patients after using of standard 
chemotherapy still ranges between 3 and 10 months (de-
pending on prognosis factors and treatment schedule). 
As many reports have shown, Poland is a country 
with a high cancer mortality which results not only 
from the magnitude of exposure to risk factors and 
low population effectiveness of screening programs, 
but also delays in the marketing authorization of new 
programs of cancer treatment compared with other EU 
countries [33]. In the current drug program, through 
which Poland regulates the financing of second line 
treatment of NSCLC patients, the usage of ALK in-
hibitors is not possible. According to the Ministry of 
Health announcement regarding the list of reimbursed 
drugs, foods for special medical purposes, and medical 
products (effective since 1 July 2015) molecular targeted 
treatment of NSCLC patients within drug programs 
includes three EGFR TKI inhibitors (erlotinib, gefitinib 
and afatinib) [34]. These drugs may be used in the first 
and the second line treatment in patients with some 
morphological subtypes of NSCLC with an activating 
mutation of the EGFR gene in a locally advanced stage 
(patients ineligible for radical surgery) or metastatic 
disease. The treatment with EGFR inhibitors allows 
for prolonged progression-free survival by 66% in this 
group of patients compared with those receiving stan-
dard chemotherapy. However, most prospective clinical 
trials failed to show any effect of EGFR on OS [35]. 
ALK inhibitors (crizotinib, ceritinib) are still outside 
the reimbursement system. It should be also noted 
that the recommendations of the Head of Polish HTA 
agency AOTM (Agencja Oceny Technologii Medycznych) 
issued in 2013 (114/2013) accorded the reimbursement 
of crizotinib with the following indication: the treatment 
of ALK (+) NSCLC within drug program, needs to be 
supplemented with currently published evidence [36]. 
Considering this, it could significantly change the per-
ception of cost-effectiveness, which is a critical issue in 
the reimbursement process of antineoplastic drugs. As 
indicated in an IMS Institute report published in 2014, in 
countries where reimbursement decisions are connected 
with restrictive assessments of cost of additional QALY 
gained, the problem with the availability of new drugs is 
observed mainly in the area of oncology [37].
Observations of molecular targeted drug develop-
ment in last decade allows one to assume that improve-
ment of access to innovative antineoplastic drugs in the 
nearest future will be mainly influenced by identifying 
new predictive factors and widespread use of genetic 
testing, performed during process of qualification for 
treatment. However, the main prerequisite will be fi-
nancing of molecular testing by publicly funded bodies 
(or drug manufacturers within so-called risk-sharing 
schemes) at a level corresponding to the real costs 
incurred by healthcare providers. The adequate se-
lection of patients to undergo high-cost treatments 
will be a significant determinant of their clinical and 
cost-effectiveness. New discoveries in pharmacology, 
pharmacogenetics and molecular biology could change 
the standards of diagnostic and therapeutic management 
and, along with them, the expectations and requirements 
of patients and their families. The next few years will 
will possibly bring a new information, which will enable 
further progress in the treatment results in patients with 
advanced lung cancer. 
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